Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease.

Lewis TL, Cao D, Lu H, Mans RA, Su YR, Jungbauer L, Linton MF, Fazio S, LaDu MJ, Li L.

J Biol Chem. 2010 Nov 19;285(47):36958-68. doi: 10.1074/jbc.M110.127829. Epub 2010 Sep 16.

2.

Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice.

Fitz NF, Cronican A, Pham T, Fogg A, Fauq AH, Chapman R, Lefterov I, Koldamova R.

J Neurosci. 2010 May 19;30(20):6862-72. doi: 10.1523/JNEUROSCI.1051-10.2010.

3.

EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity.

Bieschke J, Russ J, Friedrich RP, Ehrnhoefer DE, Wobst H, Neugebauer K, Wanker EE.

Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7710-5. doi: 10.1073/pnas.0910723107. Epub 2010 Apr 12.

4.

Fibrillar oligomers nucleate the oligomerization of monomeric amyloid beta but do not seed fibril formation.

Wu JW, Breydo L, Isas JM, Lee J, Kuznetsov YG, Langen R, Glabe C.

J Biol Chem. 2010 Feb 26;285(9):6071-9. doi: 10.1074/jbc.M109.069542. Epub 2009 Dec 15.

5.

Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses.

Yvan-Charvet L, Wang N, Tall AR.

Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):139-43. doi: 10.1161/ATVBAHA.108.179283. Epub 2009 Oct 1. Review.

6.

Mitochondrial mechanisms in amyloid beta peptide-induced cerebrovascular degeneration.

Hsu MJ, Sheu JR, Lin CH, Shen MY, Hsu CY.

Biochim Biophys Acta. 2010 Mar;1800(3):290-6. doi: 10.1016/j.bbagen.2009.08.003. Epub 2009 Aug 20. Review.

PMID:
19698762
7.

Association of cardiovascular factors and Alzheimer's disease plasma amyloid-beta protein in subjective memory complainers.

Bates KA, Sohrabi HR, Rodrigues M, Beilby J, Dhaliwal SS, Taddei K, Criddle A, Wraith M, Howard M, Martins G, Paton A, Mehta P, Foster JK, Martins IJ, Lautenschlager NT, Mastaglia FL, Laws SM, Gandy SE, Martins RN.

J Alzheimers Dis. 2009;17(2):305-18. doi: 10.3233/JAD-2009-1050.

PMID:
19363264
8.

Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease.

Bell RD, Zlokovic BV.

Acta Neuropathol. 2009 Jul;118(1):103-13. doi: 10.1007/s00401-009-0522-3. Epub 2009 Mar 25. Review.

9.

Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy.

Weller RO, Boche D, Nicoll JA.

Acta Neuropathol. 2009 Jul;118(1):87-102. doi: 10.1007/s00401-009-0498-z. Epub 2009 Feb 22. Review.

PMID:
19234858
10.

Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy.

Hawkes CA, McLaurin J.

Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1261-6. doi: 10.1073/pnas.0805453106. Epub 2009 Jan 21.

11.

Human apolipoprotein A-I binds amyloid-beta and prevents Abeta-induced neurotoxicity.

Paula-Lima AC, Tricerri MA, Brito-Moreira J, Bomfim TR, Oliveira FF, Magdesian MH, Grinberg LT, Panizzutti R, Ferreira ST.

Int J Biochem Cell Biol. 2009 Jun;41(6):1361-70. doi: 10.1016/j.biocel.2008.12.003. Epub 2008 Dec 14.

PMID:
19130896
12.

Structural classification of toxic amyloid oligomers.

Glabe CG.

J Biol Chem. 2008 Oct 31;283(44):29639-43. doi: 10.1074/jbc.R800016200. Epub 2008 Aug 22. Review.

13.

Cardiovascular risk factors and dementia.

Fillit H, Nash DT, Rundek T, Zuckerman A.

Am J Geriatr Pharmacother. 2008 Jun;6(2):100-18. doi: 10.1016/j.amjopharm.2008.06.004. Review.

PMID:
18675769
14.

CSF biomarker levels in early and late onset Alzheimer's disease.

Bouwman FH, Schoonenboom NS, Verwey NA, van Elk EJ, Kok A, Blankenstein MA, Scheltens P, van der Flier WM.

Neurobiol Aging. 2009 Dec;30(12):1895-901. doi: 10.1016/j.neurobiolaging.2008.02.007. Epub 2008 Apr 9.

PMID:
18403055
15.

Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior.

Selkoe DJ.

Behav Brain Res. 2008 Sep 1;192(1):106-13. doi: 10.1016/j.bbr.2008.02.016. Epub 2008 Feb 17. Review.

16.

Influence of tertiary structure domain properties on the functionality of apolipoprotein A-I.

Tanaka M, Koyama M, Dhanasekaran P, Nguyen D, Nickel M, Lund-Katz S, Saito H, Phillips MC.

Biochemistry. 2008 Feb 19;47(7):2172-80. doi: 10.1021/bi702332b. Epub 2008 Jan 19.

PMID:
18205410
17.

Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatment.

Lefterov I, Bookout A, Wang Z, Staufenbiel M, Mangelsdorf D, Koldamova R.

Mol Neurodegener. 2007 Oct 22;2:20.

18.
19.

The relation between apolipoprotein A-I and dementia: the Honolulu-Asia aging study.

Saczynski JS, White L, Peila RL, Rodriguez BL, Launer LJ.

Am J Epidemiol. 2007 May 1;165(9):985-92. Epub 2007 Feb 13.

PMID:
17298957
20.

Kinetics and thermodynamics of amyloid assembly using a high-performance liquid chromatography-based sedimentation assay.

O'Nuallain B, Thakur AK, Williams AD, Bhattacharyya AM, Chen S, Thiagarajan G, Wetzel R.

Methods Enzymol. 2006;413:34-74.

PMID:
17046390

Supplemental Content

Support Center